A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

NCT05893862 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Elpipodect
DRUG: Moxifloxacin
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC